Financial Performance - The company's revenue for the first quarter of 2022 was RMB 88,560 thousand, representing an increase of 9.2% compared to RMB 80,894 thousand in the same period of 2021[17] - Gross profit for the first quarter of 2022 was RMB 34,688 thousand, with a gross margin of approximately 39.2%, compared to RMB 35,304 thousand in the first quarter of 2021[17] - The net profit for the first quarter of 2022 was RMB 2,118 thousand, a significant increase from RMB 405 thousand in the same period of 2021[17] - The company’s operating profit for the first quarter of 2022 was RMB 5,393 thousand, compared to RMB 4,100 thousand in the first quarter of 2021[17] - The company reported a total comprehensive income of RMB 2,132 thousand for the first quarter of 2022, compared to RMB 421 thousand in the same period of 2021[20] - The company’s financial costs for the first quarter of 2022 were RMB 1,290 thousand, down from RMB 1,842 thousand in the same period of 2021[17] - The company reported a tax expense of RMB 1,091,000 for the three months ended March 31, 2022, compared to RMB 1,071,000 for the same period in 2021, reflecting a slight increase of 1.87%[30] - The total tax expense for the current period reflects the preferential tax rate of 15% for high-tech enterprises, compared to the standard rate of 25% in China[30] Research and Development - Research and development expenses for the first quarter of 2022 were RMB 5,074 thousand, slightly lower than RMB 5,800 thousand in the first quarter of 2021[17] - The company obtained five patent authorizations during the reporting period, enhancing its product offerings in areas such as vitamin D testing and uric acid measurement[43] Business Focus and Market Dynamics - The company continues to focus on the production, sales, and distribution of in vitro diagnostic reagents as its main business activity[23] - The in vitro diagnostic industry is experiencing significant growth, with biochemical and immunodiagnostic reagents accounting for over 50% of market demand, driven by the need for routine medical testing[40] - The company anticipates increased competition in the in vitro diagnostic market due to evolving industry dynamics and heightened market concentration[40] - The company is committed to providing high-quality and comprehensive services to its customers, aiming for product, market, and management upgrades[41] - The company is focusing on strengthening its business foundation and adjusting operational strategies to enhance service capabilities and innovate cooperation models[41] Shareholder Information - As of March 31, 2022, Mr. Chen Peng holds 10,000,000 shares, representing 12.43% of the domestic shares and 6.91% of the total registered capital[47] - Beijing Puxi Asset Management Co., Ltd. directly holds 31,308,576 shares, accounting for 38.93% of the domestic shares and 21.64% of the total registered capital[49] - Yunnan Shengneng Investment Partnership holds 12,269,648 domestic shares, which is 15.26% of the domestic shares and 13.16% of the total registered capital[49] - The company has a significant shareholder structure, with Beijing Holdings Limited holding 27,256,143 H shares, representing 42.40% of the H shares[49] - Mr. Li Yang holds 1,050,263 shares directly, which is 1.31% of the domestic shares[49] Corporate Governance - The company has adopted a code of conduct for directors regarding securities trading, ensuring compliance with GEM Listing Rules[56] - The company has confirmed that all directors complied with the standards of conduct for securities trading during the reporting period[56] - The report indicates no new strategies or market expansions were disclosed during the earnings call[51] - The company established an audit committee on February 10, 2006, to review and supervise financial reporting procedures and internal control systems[61] - As of March 31, 2022, the company complied with all provisions of the Corporate Governance Code, except for provision D.2.5[62] - The company decided not to establish an internal audit department due to its scale and simple operational structure, but has implemented measures to fulfill internal audit functions[63] - The board has engaged external consultants to conduct internal reviews as determined by the audit committee[63] - The board will periodically review the necessity of establishing an internal audit function and may form an internal audit team if needed[63] Dividends - The company did not recommend the distribution of an interim dividend for the three months ended March 31, 2022, consistent with the previous year[35] Earnings Per Share - The earnings per share for the first quarter of 2022 were RMB (0.01), consistent with the same period in 2021[17] - The basic loss per share attributable to ordinary equity holders of the parent was calculated based on a weighted average of 144,707,176 shares for both the three months ended March 31, 2022, and 2021, with no adjustments for potential dilution[31]
中生北控生物科技(08247) - 2022 Q1 - 季度财报